NCT06743620
Observational Registry for Iltamiocel Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
Enrolling by Invitation
Not specifiedAges 18+ObservationalCook MyoSite
~96 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:iltamiocel
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long term safety
Measured over 5 years
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesMassachusetts1
Study leadership
- Ron Jankowski, PhD · STUDY_DIRECTOR · Cook MyoSite, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Has completed participation within 15 months in the CLBT clinical study for females with persistent or recurrent SUI following surgical treatment (i.e., either subject has completed all follow-up visits or has been officially exited from the study).
Has received at least one dose of iltamiocel as part of the CLBT study.
Must be willing and able to comply with the study procedures, is able to understand all study requirements and must agree to read and sign the informed consent form prior to any study-related procedures.
Has access to a phone or electronic device to allow completion of electronic documents
Exclusion
Has only received placebo as part of the CLBT study.
Unable or unwilling to provide informed consent.
What this trial measures
- Long term safety5 years
Long term safety of iltamiocel
- Long term effectiveness5 years
Long term effectiveness of iltamiocel